Public Companies
Universal Ibogaine Announces Kelburn Reopening Date
Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it’s…
Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it’s research and development clinic, the Kelburn Mental Health and Addiction Recovery Center is scheduled to reopen and commence business operations on October 17, 2022 .
“Progress is going remarkably well on the renovations and program development, we have key hires in place, and we are excited to open and start helping people again. We are looking at about 50% of our expanded occupancy when we open the doors again in October as of today. We have a large referral network for clients and the situation with the addiction and opioid crisis is still only getting worse by the day so we will likely be full pretty quickly. We are also quite pleased with the progress we are making on the ibogaine clinical trial process. We will be the first legal ibogaine clinic in Canada. This could be the turning point in the opioid crisis.”
Dr Ian Rabb, Universal Ibogaine Chief Clinics Officer
About Universal Ibogaine Inc
UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics6 days ago
Psychedelics Can Offer More Than Therapy On Its Own